Bioidentical Hormone Replacement Therapy: What It Is, Risks, and How It Works

Bioidentical hormone replacement therapy (BHRT) uses hormones — most often estradiol and progesterone — that are chemically identical to hormones your body makes. FDA-approved bioidentical hormones are evidence-based options for menopause symptoms. Compounded bioidentical formulas are custom-made by pharmacies and are not FDA-approved. Both require a licensed clinician’s review because benefits and risks depend on your health history.

What is bioidentical hormone replacement therapy?

Bioidentical hormone replacement therapy means using hormones with the same chemical structure as hormones made in the human body. In menopause care, that usually means estradiol and progesterone, used to ease symptoms linked to lower estrogen levels.

The phrase can be confusing. Some FDA-approved menopause hormone therapy (MHT) products are bioidentical. Some compounded products are also bioidentical, but they are custom-mixed and not FDA-approved. The North American Menopause Society states that hormone therapy is the most effective treatment for vasomotor symptoms, but the choice of hormone, route, dose, and duration should be individualized 1.

Common symptoms that may improve with MHT include hot flashes, night sweats, sleep disruption related to night sweats, and vaginal dryness or pain with sex. Risks matter in the same conversation: systemic hormone therapy can increase the risk of blood clots, stroke, gallbladder disease, and, for some combined estrogen-progestogen regimens, breast cancer with longer use 1, 3.

How is bioidentical HRT different from traditional hormone therapy?

Bioidentical HRT describes the hormone’s structure, not whether it is safer, more natural, or FDA-approved. Most modern menopause care now includes FDA-approved bioidentical estradiol options, while older “traditional” products included hormones such as conjugated equine estrogens and medroxyprogesterone acetate.

Where the term came from

The term “bioidentical” became popular after the Women’s Health Initiative (WHI) raised concern about risks seen with one studied regimen: conjugated equine estrogens plus medroxyprogesterone acetate. In the WHI trial, combined therapy increased invasive breast cancer, coronary heart disease, stroke, and pulmonary embolism compared with placebo, while lowering fracture and colorectal cancer risk 3.

That trial was important, but it did not study every hormone, dose, route, or patient group. For example, the WHI estrogen-alone trial in women with prior hysterectomy found increased stroke risk with conjugated equine estrogen, but a different breast cancer pattern than combined therapy 4. This is why clinicians avoid one-size-fits-all answers.

Why most modern MHT is already bioidentical

Many FDA-approved estradiol products use 17-beta estradiol, the main estrogen made by the ovaries before menopause. FDA-approved micronized progesterone is also bioidentical progesterone, and its labeling includes use with estrogen in postmenopausal people with a uterus to reduce the risk of endometrial hyperplasia 5.

So the key question is not only “bioidentical or not?” A better question is: Which hormone, which route, which dose range, which uterus status, and which risk profile? Side effects can include breast tenderness, nausea, headache, mood changes, spotting, bloating, and sleepiness with progesterone; more serious risks require clinician screening 1, 5.

FDA-approved vs compounded bioidentical hormones: what is the difference?

FDA-approved bioidentical hormones have been reviewed for manufacturing quality, dose consistency, labeling, and safety information. Compounded bioidentical hormones are made for an individual prescription by a pharmacy, often a 503A compounding pharmacy, and are not FDA-approved.

What FDA approval covers

FDA approval means the product has an approved label, defined ingredients, quality standards, and manufacturing oversight. Estradiol product labeling states that systemic estrogen therapy may increase risks such as stroke and deep vein thrombosis and should use the lowest effective dose for the shortest duration consistent with treatment goals and risks 6.

FDA-approved products are not risk-free. They still require screening for contraindications, including breast cancer history, unexplained vaginal bleeding, active or past blood clots, stroke, heart attack, liver disease, and known hypersensitivity to ingredients listed in the product label 5, 6.

What compounded means and why it matters

Compounding means a pharmacy prepares a medication for a specific patient based on a clinician’s prescription. ACOG states that compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations are available, because claims of greater safety or effectiveness are not supported by high-quality evidence 2.

The concern is not that every compounded medication is unsafe. The concern is that compounded formulas do not go through FDA approval for safety, effectiveness, potency, or labeling. ACOG and the Endocrine Society both warn that compounded products may have variable dose delivery, purity, and safety information compared with FDA-approved products 2, 7.

When compounding may be medically appropriate

Compounding may be considered when a patient cannot use an available manufactured product because of an allergy, intolerance, swallowing issue, or a needed formulation that is not otherwise available. That decision should be made by a licensed clinician and pharmacist, with clear counseling about the limits of compounded products 2.

At Chia, we emphasize the safer axis that matters in real life: licensed care versus unlicensed sourcing. A clinician-reviewed prescription through a state-licensed 503A pharmacy is very different from buying hormones or pellets from a no-prescription website.

Which hormones are used in BHRT?

Estradiol and progesterone are the main hormones used in bioidentical menopause care. Other hormones, including estriol, estrone, testosterone, and DHEA, may come up in marketing or specialty care, but the evidence and legal status differ.

Estradiol

Estradiol, also called 17-beta estradiol, is the main estrogen that drops during perimenopause and menopause. FDA-approved estradiol products are indicated for moderate to severe vasomotor symptoms and some vulvar and vaginal symptoms of menopause, depending on the product label 6.

Estradiol can help hot flashes and night sweats, but it can also cause breast tenderness, headache, nausea, spotting, and fluid retention. Systemic estrogen may increase risks such as stroke, blood clots, and gallbladder disease, so clinician screening matters 1, 6.

Micronized progesterone

Progesterone is used with systemic estrogen in people who still have a uterus. Its key role is to reduce the risk of endometrial hyperplasia, a thickening of the uterine lining that can occur when estrogen is used without enough progestogen 5.

Micronized progesterone can cause sleepiness, dizziness, breast tenderness, bloating, mood changes, and irregular bleeding. People with peanut allergy should note that some FDA-approved progesterone capsules contain peanut oil, so ingredient review is important 5.

Estriol and estrone

Estriol and estrone are estrogens made by the body, but they are not the main systemic hormones used in standard US menopause therapy. Estriol is often promoted in compounded products, yet ACOG notes that evidence is limited and compounded formulations should not be marketed as safer or more effective than FDA-approved options 2.

Because these are still estrogens, possible risks include breast tenderness, bleeding, endometrial stimulation if used without adequate progesterone in someone with a uterus, and systemic estrogen risks depending on dose and absorption 2, 6.

Testosterone in women

Testosterone therapy in women is off-label in the United States. A global consensus statement found the clearest evidence for carefully selected postmenopausal women with hypoactive sexual desire disorder, but it did not support testosterone for general energy, mood, cognition, or anti-aging claims 8.

Side effects can include acne, unwanted hair growth, scalp hair thinning, voice changes, and changes in lipids depending on dose and formulation. The consensus statement also notes that long-term safety data are limited, so monitoring and avoiding supraphysiologic levels are important 8.

DHEA

DHEA, or dehydroepiandrosterone, is a hormone precursor. A prescription vaginal DHEA product is FDA-approved for moderate to severe pain with sex due to menopause-related vulvar and vaginal atrophy, while oral DHEA supplements are different products and should not be assumed to have the same evidence 9.

DHEA can cause androgen-like side effects such as acne or unwanted hair growth, and systemic hormone effects may be unpredictable with supplements. People with hormone-sensitive cancers or unexplained bleeding should not self-start DHEA without a clinician review 9.

What forms does bioidentical HRT come in?

Bioidentical HRT can come as pills, capsules, patches, gels, sprays, creams, vaginal inserts, rings, injections, and pellets. Route matters because oral, skin, vaginal, and implanted forms can have different absorption patterns, side effects, and monitoring needs.

For menopause symptoms, route is part of risk management. NAMS notes that transdermal routes and lower doses may decrease risk of venous thromboembolism and stroke, but comparative randomized trial data are limited 1.

What symptoms can bioidentical HRT help with?

Menopause hormone therapy can help vasomotor symptoms, meaning hot flashes and night sweats, and it can help some menopause-related vaginal and urinary symptoms. Individual results vary, and symptom goals should be weighed against risks at each follow-up.

The strongest evidence is for vasomotor symptoms. NAMS states hormone therapy is the most effective treatment for hot flashes and night sweats and is also effective for genitourinary syndrome of menopause, which includes vaginal dryness and pain with sex 1.

Timing matters. For healthy women younger than 60 years or within 10 years of menopause onset, NAMS describes the benefit-risk ratio as generally favorable for bothersome vasomotor symptoms and fracture prevention; for women older than 60 or more than 10 years from menopause onset, absolute risks of coronary heart disease, stroke, blood clots, and dementia are higher 1.

Hormone therapy should not be framed as an anti-aging plan. Large trials and professional guidance do not support starting systemic hormone therapy to prevent chronic disease in otherwise asymptomatic postmenopausal people 1, 10.

What are the risks and side effects of BHRT?

BHRT carries real risks, even when the hormones are bioidentical. Risk depends on age, time since menopause, personal and family history, uterus status, route, dose, and how long therapy continues.

Common side effects

Common side effects can include breast tenderness, bloating, nausea, headache, mood changes, spotting or bleeding, skin irritation with patches, and sleepiness or dizziness with progesterone. New, heavy, or unexplained bleeding after menopause needs medical evaluation 5, 6.

Cardiovascular and clot risk

Systemic estrogen therapy can increase the risk of stroke and venous thromboembolism, including deep vein thrombosis and pulmonary embolism. In WHI, combined conjugated equine estrogen plus medroxyprogesterone acetate increased stroke and pulmonary embolism risk compared with placebo 3.

Risk is not the same for every person or every route. NAMS notes that age, time since menopause, dose, and route all affect the benefit-risk balance, and that transdermal routes may have lower clot and stroke risk than oral routes, though direct trial evidence is limited 1.

Breast cancer risk

Breast cancer risk depends on the regimen. WHI combined estrogen-progestin therapy increased invasive breast cancer risk, while WHI estrogen-alone therapy in women with hysterectomy did not show the same pattern during the intervention period 3, 4.

This does not mean estrogen-alone therapy is right for everyone, and it is usually not used without progesterone in people who still have a uterus because of endometrial cancer risk. A clinician should review mammogram history, breast cancer risk, uterus status, and bleeding history before prescribing 1, 5.

Risks unique to compounded formulations

Compounded bioidentical hormone therapy can add uncertainty because potency, absorption, and labeling may differ from FDA-approved products. ACOG states there is a lack of high-quality safety and effectiveness data for compounded bioidentical menopausal hormone therapy, and that patient counseling should include FDA-approved options and risks of compounding 2.

Pellets deserve special caution because once placed under the skin, they may be hard to adjust quickly if side effects occur. ACOG notes concerns about pellet dosing and lack of safety data for many compounded pellet approaches 2.

Who is not a good candidate for bioidentical hormones?

Some people should not use systemic hormone therapy unless a specialist determines otherwise. Screening is essential because “bioidentical” does not remove standard hormone-therapy contraindications.

• Known, suspected, or prior breast cancer or estrogen-sensitive cancer, unless a specialist specifically guides care 6
• Unexplained vaginal bleeding, because the cause should be evaluated before estrogen or progesterone is started 6
• Active or prior blood clot, pulmonary embolism, stroke, or heart attack, depending on the product label and clinical history 5, 6
• Active liver disease or known serious liver dysfunction 5, 6
• Pregnancy, suspected pregnancy, or breastfeeding unless a clinician determines a different indication applies 5, 6
• Known allergy or hypersensitivity to a product ingredient, including ingredient-specific issues such as peanut oil in some progesterone capsules 5

People with migraine with aura, high blood pressure, high triglycerides, gallbladder disease, strong family history of breast cancer, smoking history, clotting disorders, or complex medication lists may still be candidates in some cases, but they need a careful risk review. This is one reason we use a clinician-reviewed intake rather than a one-click purchase.

How much does bioidentical HRT cost?

Bioidentical HRT cost varies by route, pharmacy, insurance coverage, labs, visits, and whether the product is FDA-approved or compounded. Pellet programs and custom compounds often cost more out of pocket than standard oral or transdermal prescriptions.

FDA-approved products may be covered by insurance, but copays vary widely. Compounded bioidentical hormones are often cash-pay because they are custom-prepared and not FDA-approved. Lab testing may add cost when clinically needed, but major societies caution against using salivary or serum hormone levels alone to “custom dose” compounded menopause hormones because levels can fluctuate and may not predict symptom control 2, 7.

Chia’s live catalog lists the HRT for Women protocol, but no monthly starting price is listed in the current offering block. The protocol page is the right place to check current details before starting an eligibility review.

How do you start bioidentical HRT online, and how does Chia’s HRT for Women protocol work?

Starting BHRT online should still include a real medical review. At Chia, our HRT for Women protocol uses oral estradiol and immediate-release progesterone, prescribed only when a licensed US provider decides it is clinically appropriate.

The process starts with a short online health questionnaire through Chia. A licensed US provider reviews your symptoms, medical history, medication list, and risk factors. If hormone therapy is appropriate, your medication is compounded by a US state-licensed 503A pharmacy and shipped to your door.

Dosing is provider-guided and adjusted over time. You can message your care team through the patient portal between visits. A prescription is never guaranteed, and compounded medications are not FDA-approved.

We separate these categories because hormone therapy is not the same as a general longevity protocol. If your main concern is hot flashes, night sweats, or menopause-related sleep disruption, the HRT conversation is different from the conversation about peptides or metabolic health.

If you are unsure where you fit, you can begin with the eligibility quiz. It helps route your information for a clinician review, but it does not replace the provider’s medical judgment.

What should you ask before starting BHRT?

A good BHRT visit should cover benefits, risks, alternatives, and follow-up. The goal is not to chase a lab number; it is to decide whether hormone therapy fits your symptoms, health history, and preferences.

1. 1What symptoms are we trying to improve, and how will we measure response?
2. 2Do I need progesterone because I still have a uterus?
3. 3Which route makes sense for my risk profile: oral, skin, or vaginal?
4. 4What side effects should prompt a message or urgent care visit?
5. 5How often should we reassess whether I still need therapy?
6. 6Are there non-hormonal options I should consider for hot flashes, sleep, mood, or vaginal symptoms?

Professional guidance supports periodic reevaluation rather than automatic long-term continuation. NAMS states that longer treatment durations should be for documented indications such as persistent vasomotor symptoms, with shared decision-making and periodic review 1.

Keep reading

GLP-1 Weight Loss

How to Get Weight Loss Injections: A Step-by-Step Guide

GLP-1 Weight Loss

GLP-1 Injections Online: How to Get a Prescription, What They Cost, and What to Watch For

Peptides

Peptide Injections: What They Are, How They Work, and What to Expect